SMS Pharmaceuticals share news, announcements and annual reports
NSE: SMSPHARMABSE: 532815Pharmaceuticals & BiotechnologySmall Cap
SMS Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2007
Last close ₹511.35up ₹25.55 (5.26%)BSE ₹511.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹485.80.
30 Oct: open ₹499.70, high ₹525.00, low ₹482.20
52-week range of traded prices to 30 Oct 2026
₹270.10Low, 24 Nov 2025₹525.00High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,789 Cr920th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.63
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 43,04,85521.5% delivered
SMS Pharmaceuticals board meetings
148 filed, newest first. Page 3 of 3.
Aug 2014
18 Aug · Board meeting
Inter alia, to consider the following items of Agenda: 1. To approve the draft Directors' Report. 2. To approve the draft Notice of the 26th Annual General Meeting of the Company. 3. To fix the time, date, book closure and venue to convene the 26th Annual General Meeting of the Company. 4. To re-appoint the Statutory Auditors.1 Aug · Board meeting
Inter alia, to consider the Un-audited Financial results of the Company for the quarter ended June 30, 2014 with limited reveiw report.
May 2014
20 May · Board meeting
Interalia, to consider the followings:- (1) To consider, approve and take on record the Audited Annual Accounts for the year ended March 31, 2014; (2) To consider recommendation of the Dividend, if any, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.
Feb 2014
3 Feb · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended December 31, 2013 with limited review report.
Oct 2013
31 Oct · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended September 30, 2013 with limited review report.
Aug 2013
16 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 13, 2013 has taken the following decisions: 1. Considered and approved Re-appointment of Mr. Ramesh Babu Potluri as CMD for a period of 3 years w.e.f. December 01, 2013 subject to necessary approvals. 2. Considered and approved Re-appointment of Mr. TVVSN Murthy as VC&JMD for a period of 3 years w.e.f. December 01, 2013 subject to necessary approvals. 3. Considered and approved Re-appointment of Mr. T. V. Praveen as Vice-President (Marketing) for a further period of 3 years w.e.f. January 01, 2014 subject to necessary approvals. 4. Considered and approved appointment of Mr. Vamsi Krishna Potluri as Vice-President (Operations) for a period of 3 years w.e.f. August 09, 2013 subject to necessary approvals. 5. Considered and approved to invest upto Rs. 30.00 crores in M/s. VKT Pharma Private Limited by way of Equity participation subject to necessary approvals. 6. Considered and authorized the CMD to evaluate the possibilities of the low-performing assets to consolidate with existing facilities to reduce the operating overheads and also for better utilization of the said facilities.2 Aug · Board meeting
Inter alia, to consider the followings: (1) To consider the un-audited financial results for the quarter ended on June 30, 2013 with limited review report. (2) To consider the Re-appointment of Mr. Ramesh Babu Potluri as Chairman & Managing Director of the Company for a further period of 5 years with effect from December 01, 2013. (3) To consider the Re-appointment of Mr. TVVSN Murthy as Vice-Chairman & Joint Managing Director of the Company for a further period of 5 years with effect from December 01, 2013. (4) To consider the Re-appointment of Mr. T. V. Praveen as Vice-President (Marketing) of the Company for a further period of 5 years with effect from January 01, 2014. (5) To consider the appointment of Mr. Vamsi Krishna Potluri as Vice-President (Operations) of the Company. (6) To Invest in M/s. VKT Pharma Private Limited. (7) To fix the date, time and venue of Annual General Meeting of the Company. (8) To fix the date of book closure for the purpose of conduct of Annual General Meeting and payment of dividend.
May 2013
11 May · Board meeting
Interalia, to consider the followings :- (1) To consider, approve and take on record the Audited Annual Accounts for the year ended March 31, 2013; (2) To consider recommendation of the Dividend, if any, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.
Feb 2013
26 Feb · Board meeting
18 Feb · Board meeting
Interalia, to consider the proposal for Buy Back of Company's Shares in accordance with Section 77A of the Companies Act, 1956 and the Article of the Association of the Company.5 Feb · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended December 31, 2012 with limited review report.
Oct 2012
31 Oct · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended September 30, 2012.17 Oct · Board meeting
Board of Directors of the Company at its meeting held on October 16, 2012, inter alia, has taken the following decision: (1) The Board identified and finalised "Mylan Laboratories Ltd" as buyer out of the proposals received.(2) The Board considered and approved the Sale consideration for Unit -VI situated at Plot No 28, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam, A.P., as Indian Rupees 173.00 Crores (Indian Rupees One Hundred and Seventy Three Crores only).15 Oct · Board meeting
Company had informed the Exchange that the Board of Directors of the Company scheduled to be held on October 13, 2012 Interalia, to consider the following items of Agenda:- (1) To consider and ratify the Scrutinizer's Report for Postal Ballot. (2) To consider and approve the valuation report of M/s. M.M. Reddy & Company, Chartered Accountants.(3) To finalise and approve the prospective buyer and to finalise the consideration for Sale of the Unit-VI of the Company. (4) To finalize and approve the terms and conditions of the draft Agreement of Sale of Unit-VI. (5) To authorize CMD for execution of the Agreement of Sale.(6) To appoint authorized signatory for execution of Sale Deed. The Company has now informed the Exchange that due to administrative convenience the aforesaid board meeting scheduled to be held on October 13, 2012 has been postponed on October 16, 2012.8 Oct · Board meeting
Interalia, to consider the following items of Agenda:- (1) To consider and ratify the Scrutinizer's Report for Postal Ballot. (2) To consider and approve the valuation report of M/s. M.M. Reddy & Company, Chartered Accountants.(3) To finalise and approve the prospective buyer and to finalise the consideration for Sale of the Unit-VI of the Company. (4) To finalize and approve the terms and conditions of the draft Agreement of Sale of Unit-VI. (5) To authorize CMD for execution of the Agreement of Sale.(6) To appoint authorized signatory for execution of Sale Deed.
Aug 2012
21 Aug · Board meeting
14 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 10, 2012 has not recommended Dividend for the year 2011-12 to the shareholders keeping in view of the Conservation of the resources.11 Aug · Board meeting
Interalia, to consider the following items of Agenda:- (1) To consider the sale and transfer of Unit-VI situated at J.N. Pharma City, Parawada, Visakhapatnam, A.P. (2) To appoint Independent Valuers and legal advisors. (3) To appoint Scrutinizer. (4) To consider and approve the Notice of Postal Ballot. (5) To appoint Director/Chief Financial Officer for the entire poll process.2 Aug · Board meeting
Interalia, to consider the followings :- (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2012; (2) To recommend the Dividend for the year 2011-12, if any; (3) To consider and approve the Unaudited Financial Results for the quarter ended on June 30, 2012; (4) To fix the time, date and venue to convene the Annual General Meeting of the Company; (5) To approve the draft notice to convene the Annual General Meeting of the Company; (6) To fix the date of closure of Register of Members and Share Transfer Books for the purpose of payment of dividend if any and to convene the Annual General Meeting of the Company.
May 2012
11 May · Board meeting
Board of Directors of the Company at its meeting held on May 10, 2012 has Appointed Mr. Utpal Gokhale, as a new nominee Director of Exim Bank in place of Mr. K. Umamaheswaram.
Apr 2012
23 Apr · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended March 31, 2012 with limited review report.
Jan 2012
20 Jan · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended December 31, 2011 with limited review report.
Oct 2011
25 Oct · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended September 30, 2011.
Jul 2011
28 Jul · Board meeting
Interalia, to consider the followings :- (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2011; (2) To recommend the Dividend for the year 2010-11, if any; (3) To consider and approve the Unaudited Financial Results for the quarter ended on June 30, 2011; (4) To fix the time, date and venue to convene the Annual General Meeting of the Company; (5) To approve the draft notice to convene the Annual General Meeting of the Company; (6) To fix the date of closure of Register of Members and Share Transfer Books for the purpose of payment of dividend if any and to convene the Annual General Meeting of the Company.
Apr 2011
28 Apr · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended March 31, 2011.
Jan 2011
10 Jan · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended December 31, 2010.
Oct 2010
15 Oct · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended September 30, 2010.
Aug 2010
9 Aug · Board meeting
To consider the following: (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2010. (2) To recommend the Dividend for the year 2009-10, if any. (3) To fix the time, date and venue to convene the Annual General Meeting of the Company. (4) To approve the draft notice convening the Annual General Meeting of the Company. (5) To fix the date of closure of Register of Members and Share Transfer Books for the purpose of dividend and Annual General Meeting.
Jul 2010
5 Jul · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the quarter ended June 30, 2010.
May 2010
3 May · Board meeting
Interalia, to consider the Un-audited Financial Results of the company for the quarter ended March 31, 2010.
Jan 2010
7 Jan · Board meeting
Interalia, to consider the Un-audited Financial Results of the company for the quarter ended December 31, 2009.
Oct 2009
21 Oct · Board meeting
Meeting on 28 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
25 Jul · Board meeting
For considering the Audited Annual Accounts for the year ended on March 31, 2009.6 Jul · Board meeting
Meeting on 25 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
May 2009
4 May · Board meeting
In the Board Meeting held on April 30, 2009, the Board has taken the following decisions: 1) Authorised Mr. P. Ramesh Babu, Chairman & Managing Director of the Company for Appointment of Cost Auditor for the year 2008-09. 2) Appointment of Dr. Ayman Shali, Nominee Director of Gulf Pharmaceutical Industries, U.A.E. in place of Mr. Abdul Razzaq Yousef.
Apr 2009
1 Apr · Board meeting
Interalia to consider the un-audited financial results of the Company for the quarter ended on March 31, 2009.
Jan 2009
19 Jan · Board meeting
Meeting on 27 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Nov 2008
21 Nov · Board meeting
To consider the followings: (1) To consider and approve the Audited Annual Accounts for the year ended on March 31, 2008. (2) To consider the payment of dividend for the year 2007-08, if any. (3) To fix the date of Annual General Meeting of the Company. (4) To consider any other matter with the permission of the chair.3 Nov · Board meeting
Board of Directors of the Company at its meeting held on October 31, 2008 has taken the following decisions: (1) Re-appointed Mr. P. Ramesh Babu, CMD for a further period of 5 years with effect from December 01, 2008. (2) Re-appointed Mr. TVVSN Murthy, VC & JMD for a further period of 5 years with effect from December 01, 2008.
Oct 2008
20 Oct · Board meeting
Interalia, to consider :- 1) The un-audited financial results of the Company for the quarter ended on September 30, 2008. 2) Re-appointment of Mr. P. Ramesh Babu, Chairman and Managing Director. 3) Re-appointment of Mr. TVVSN Murthy, Vice-chairman and Jt. Managing Director.
Jul 2008
21 Jul · Board meeting
Meeting on 30 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Apr 2008
22 Apr · Board meeting
Meeting on 30 Apr 2008: “Unaudited Financial Results for the qtr ended March 31, 2008”
Jan 2008
19 Jan · Board meeting
Meeting on 31 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Oct 2007
17 Oct · Board meeting
Meeting on 29 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Aug 2007
20 Aug · Board meeting
To consider the followings : 1) To consider and approve the Audited Annual Accounts for the year ended on March 31, 2007 ; 2) To consider the payment of dividend for the year 2006-07 if any ; 3) To fix the date of Annual General Meeting of the Company ; 4) To consider any other matter with the permission of the Chair.
Jul 2007
30 Jul · Board meeting
In our Board Meeting held on 30.07.2007 the Board has taken the following decisions :- 1) Considered and approved the Un-audited Financial Results for the quarter ended on 30th June, 2007. 2) Appointment of Mr. Abdul Razzaq Yousef, CEO of Gulf Pharmaceutical Industries, U.A.E. as Additional Director in the Board of Directors of the Company. Mr. Abdul Razzaq Yousef, is aged about 40 years and he did his master degree from University of Miami, USA. He joined in Gulf Pharmaceuticals in the year 1986 and had been associated with the Company till date. He has vast Experience in the area of Strategy Formulations, Project Planning and Development. His other directorships are 1) Consulting Engineering group, UAE, RAK. 2) Gulf Pharmaceutical Industries, UAE. As you are aware that Gulf Pharmaceutical Industries has 9% Equity Shares in our Company18 Jul · Board meeting
Meeting on 30 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Apr 2007
23 Apr · Board meeting
Interalia, to consider the un-audited financial results of the company for the quarter ended on March 31, 2007.